Case Study #1 GUIDING PRINCIPLES FOR THE CARE OF OLDER ADULTS WITH MULTIMORBIDITY

Similar documents
Patient-centered Care and Multimorbidity. Journal Club Christina Rincón, MD December 6, 2012

Academic Profiles: Current Position: Evidence-Based Medicine CEEBM

MEDICATION APPROPRIATENESS FOR THE AGING POPULATION. Building Partnerships for Successful Aging

Shared decision making for stepdown and stopping decisions. Michael R. Gionfriddo Pharm.D, Ph.D Geisinger Center for Pharmacy Innovation and Outcomes

Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia

The patient with multiple chronic conditions: balancing guidelines and patient preference

BLCS 1-Clinical Overview. Dr. Chris Rauscher Clinical Lead Shared Care Polypharmacy Risk Reduction Initiative

Caroline S. Blaum, MD, MS Diane and Arthur Belfer Professor of Geriatrics Director, Division of Geriatric Medicine New York University Langone

Polymedication in nursing home. Graziano Onder Centro Medicina dell Invecchiamento Università Cattolica del Sacro Cuore Rome - Italy

Integrating Goals of Care Discussions into Routine Care

Deprescribing: A Practical Guide

Special thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic

DEPRESCRIBING IN THE ELDERLY

Perfect Endings. Home Alone. Senior Estimate. Staying Alive. Medication Madness

One of the greatest challenges in geriatrics is the provision

GRADE, EBM and Deprescribing. Kevin Pottie MD CCFP, MClSc, FCFP Associate Professor, Family Medicine, University of Ottawa

Update in Geriatrics: Choosing Wisely Primum Non Nocere

Polypharmacy and the Older Adult. Leslie Baker, PharmD, BCGP Umanga Sharma, MD

Appropriate prescribing and deprescribing for older people getting it right. Alan Davis Northland District Health Board

Polypharmacy, Medication Nihilism, and the art of de-prescribing

ENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS

If a bad thing is happening to a patient, a drug did it until proven otherwise

Choosing Wisely Campaign. Lynn McNicoll, MD Alpert Medical School of Brown University Division of Geriatrics and Palliative Medicine

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary

Akinbolade O, Husband A, Forrest S, Todd A. Deprescribing in advanced illness. Progress in Palliative Care 2016, 24(5),

Therapeutic Benefits of Caregiver Interventions

Thank You to Our Sponsors: Evaluations & CE Credits. Featured Speakers. Conflict of Interest & Disclosure Statements 10/18/2016

About ISMP Canada. Analysis Outputs: Safety Bulletins. Less is More: An Introduction to Deprescribing. canada.org

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE

Frailty. Nicholas Butler MD, MBA Department of Family Medicine University of Iowa

Less is More: Introduction to Deprescribing

Changing Patterns in Medication Use with Increasing Probability of Death for Older Medicare Beneficiaries

SAFETY CONCERNS WITH MULTIPLE MEDICATIONS AND BEYOND. Sandra Brownstein, PharmD, CGP

Executive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5

Health Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions

Polypharmacy and Polymorbid Patients: Practical Tips and Tricks

Understanding Dying in America

Finding the sweet spot: Individualized targets for older adults with Type 2 DM

Polypharmacy in the Elderly

Patient Safety in Older Adults

Patient Safety in Older Adults

Supplemental materials for:

Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care

Politerapia e interazioni negli anziani: possibili interventi

Polypharmacy & De-prescribing In Older Adults

Anthony J. Caprio, MD, CMD, AGSF 1

Patient-Centered Measurement: Innovation Challenge Series

Faculty/Presenter Disclosure

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director

HHS Public Access Author manuscript Int J Clin Pharm. Author manuscript; available in PMC 2016 October 01.

Safe, effective, affordable drug choices: online tool for payers and patients.

Appendix 2 (continued): Recommendations for the management of mild to moderate dementia, dementia with a cerebrovascular component, and for addressing

Paul E. Stander, MD, MBA, FACP Division of Palliative Care Geriatrics and Extended Care Phoenix VAHS

Appendix K: Evidence review flow charts

Long-Term Care Updates

Dementia of the Alzheimer Type: the Drug Treatment Debate

End of Life Care in IJN Our journey. Dato Dr. David Chew Soon Ping Consultant Cardiologist National Heart Institute Malaysia

Tools for Targeting High Risk Patients in Your Practice. Statement of Disclosure

NeuroPI Case Study: Palliative Care Counseling and Advance Care Planning

It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia

Choosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care

Healthy Coping. Learning You Have Diabetes. Stress. Type of Stress

OVERALL CLINICAL BENEFIT

NQF Members NQF Staff Voting Draft Report: NQF-Endorsed Measures for Cardiovascular DA: October 17, 2016

Public Dissemination Effective: January 2018

A Palliative Approach in Caring for the Person and Family Living with Dementia Hospice and Palliative Nurses Association (HPNA) Online Education

General Principles for the Use of Pharmacological Agents for Co- Occurring Disorders

The Use of Sleep Aids in Our Society Today

Dr. W. Dalziel Professor, Geriatric Medicine Ottawa Hospital. November /20/ Safety: Falls/Cooking/Unsafe Behaviour. 2.

Resident Assessment Best Practices M E G A N M. G R A E S E R, D N P, G N P - BC P H Y S I C I A N H O U S E C A L L S, L L C

IPAP PTSD Algorithm -- Addenda

KANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998

The Role of Palliative Care in Advanced Lung Disease

Known as both a thief and murderer,

NBPDP Drug Utilization Review Process Update

NICE guideline Published: 21 September 2016 nice.org.uk/guidance/ng56

Deprescribing Unnecessary Medications: A Four-Part Process

recommendations should I care?

Doreen Wan-Chow-Wah, MD, FRCPC Assistant Professor, Division of Geriatric Medicine, Department of Medicine McGill University Health Center Associate

ONCOLOGY NURSING SOCIETY RESEARCH AGENDA. M. Tish Knobf, PhD, RN, AOCN, FAAN ONS Research Agenda Team Leader

Neuropsychiatric Syndromes

Advancing the Science of Patient Input in Medical Product R&D: Towards a Research Agenda

Beers Criteria: Practical Considerations. A Clinician Education Tool. Curt Wood, RPh, CGP, FASCP

Fidelity and Outcomes in Community Care

Geriatric Grand Rounds

LIGHTENING THE LOAD Reducing pill burden with appropriate discontinuation strategies

Supportive Care and Medicine Matters in the older cancer patients: The Asian Perspective

Frequently Asked Questions About Dementia

Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Strategies in Establishing Patient Centered Pain Management Goals

Health Resource Review - Section 2.4

Transitions Guidelines: Chronic Illness Management. Revised 2016

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA

Results of the liberalisation of Medisave for a population-based diabetes management programme in Singapore

Medications for Alzheimer s disease: are they right for you?

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

The Role of Palliative Care in the Management of Advanced Heart Failure

Transcription:

Case Study #1 GUIDING PRINCIPLES FOR THE CARE OF OLDER ADULTS WITH MULTIMORBIDITY Panel Moderator & Panelists: Edward Perrin, MD Banner icare Scott Bolhack, MD, MBA Sandra Brownstein, PharmD Paige Hector, LMSW TLC HealthCare Companies United Healthcare Community Plan Page Ahead Healthcare Education & Consulting Learning Objectives: Develop an approach by which clinicians can care optimally for patients with multimorbidity. Incorporate elements from five primary domains while providing care for older patients with multimorbidity. DISCLOSURE OF COMMERCIAL SUPPORT Scott Bolhack, MD, MBA, Paige Hector, LMSW and Edward Perrin, MD do not have a significant financial interest or other relationship with manufacturer(s) of commercial product(s) and /or provider(s) of commercial services discussed in this presentation Sandra Brownstein, PharmD is an employee of United Healthcare. 1

Edward Perrin, MD Scott Bolhack, MD Sandra Brownstein, PharmD Paige Hector, LMSW Guiding Principles: The Care Of Older Adults With Multimorbidity Fall Symposium Arizona Geriatrics Society November 9, 2013 Background Multi-morbidity = multiple chronic conditions 75% of adults >65 have > 3 chronic conditions Goal for Health People 2020 (HHS) Improve the health, function, and quality of life of older adults. Background Guidelines for specific diseases do not apply to people with multiple conditions Multi-morbid are excluded or underrepresented from studies Guidelines for one disease counter guidelines for others Impractical Irrelevant Harmful 2

Background No one knows best way to manage older adults with multimorbidity Patients with the same conditions warrant different approaches because the patients are different Illness severity Preferences Goals Prognosis Functional status Financial status Social setting Human resources Background AGS convened expert panel Developed principles, not guidelines An approach to patients, not specific recommendations for specific conditions Secondary goal is to facilitate research and development of evidence Clinical Assessment of patient priorities Prognosis Optimization of care plans Domains 5 Domains that govern approach to older patients with multimorbidity Can be applied in any order 1. Patient Preferences 2. Interpreting the Evidence 3. Prognosis 4. Clinical Feasibility 5. Optimizing therapies and care plans 3

Limitations Time-consuming Fear of litigation Changing landscape Clinical Regulatory Social Treatments/decisions contradict one another Domains 1. Patient preferences 2. Interpreting the evidence 3. Prognosis 4. Clinical feasibility 5. Optimizing therapies and care plans Patient Preferences ALL clinical decisions require elicitation of Patient Preferences Patient-centered, but acknowledge that family, caregivers, social support also important Some patients may defer to others, including clinicians, but still want their opinions to inform the decision Recognize personal and cultural contexts Decisions change over time Preferences must be re-examined and reevaluated Elicitation of preferences is more involved when more complex decisions are faced, less involved when less complex 4

Patient Preferences Important to recognize when decisions are preference-sensitive Therapies that improve one condition but worsen another Therapies that confer long-term benefit at short-term cost Therapies that are complex with complex risks-benefit balances Preferences Decisions Patient Preferences Important to provide true informed consent Side effects often discounted by providers, but are very important to patients Describe risk-benefit in numbers, rather than vague terms ( rarely, frequently ) Use absolute risk, not relative risk Use visual aids Only after above reviewed should preferences be elicited Patient Preferences Often preferable to elicit preferences regarding general outcomes/goals, rather than specific Live as long as possible Maintain function Be pain-free Each option can be weighted according to these general goals Decisions/choices do not have to be honored when futility is present Reasonable expectation of benefit must be present 5

Domains 1. Patient preferences 2. Interpreting the evidence 3. Prognosis 4. Clinical feasibility 5. Optimizing therapies and care plans Interpreting the Evidence Very little evidence exists to guide care of older patients with multimorbidity Interpreting the Evidence Does the existing evidence apply to this patient with multimorbidity? Did study population resemble this patient? What is the quality of the evidence? Were the outcomes meaningful to this patient? Surrogate vs. patient-oriented Were adverse events adequately reported? Clinical Complexity Financial Effects on other conditions Interactions with other conditions/medications Absolute risk should be calculated if not presented Time horizon to benefit, not just NNT/NNH 6

Domains 1. Patient preferences 2. Interpreting the evidence 3. Prognosis 4. Clinical feasibility 5. Optimizing therapies and care plans Prognosis Prognosis informs, but does not dictate, decisions Most older patients want to discuss Prognosis Need to follow ethical principles Decision is also informed about preferences Prolongation of life Maintenance of function Disease-specific outcomes Quality of life Prognosis Discussions about Prognosis occur during: Decisions about treatment or prevention Decisions about screening Changes in clinical status Changes in health service utilization 7

Prognosis Not just mortality Decisions can be focused on outcomes that are: Short-term Medium-term Long-term For poorer Prognosis patients, short-term decisions are more salient, and vice versa Many prognostic calculators exist Recognize limitations Domains 1. Patient preferences 2. Interpreting the evidence 3. Prognosis 4. Clinical feasibility 5. Optimizing therapies and care plans Clinical Feasibility Treatment complexity and burden must be reviewed and discussed, including: Steps in the task Number of choices Duration of execution Informed consent Intervening and interrupting tasks 8

Clinical Feasibility The more complex or burdensome a treatment is: Adherence declines Adverse reactions increase Quality of life declines Economic burden increases Caregiver strain and depression increase Domains 1. Patient preferences 2. Interpreting the evidence 3. Prognosis 4. Clinical feasibility 5. Optimizing therapies and care plans Optimizing Therapies And Care Plans Identify treatments that are inappropriate and therapeutic omissions Medications Polypharmacy Procedures Non-pharmacologic Avoidance of prescribing cascade Explanation of risk/benefit, in addition to explanation of unknown risk/benefit or uncertainty 9

Optimizing Therapies And Care Plans Discontinuation of medications Detailed documentation One at a time Tapering Time-limited withdrawal Team approach Domains 5 Domains that govern approach to older patients with multimorbidity Can be applied in any order 1. Patient preferences 2. Interpreting the evidence 3. Prognosis 4. Clinical feasibility 5. Optimizing therapies and care plans 1. Inquire about the patient s primary concern, and any additional objectives 2. Conduct complete review of 6. Consider Prognosis 7. Consider interactions within and among treatments and conditions care plan OR focus on specific 8. Weigh benefits and harms of aspect of care plan all elements of treatment 3. Identify current medical plan conditions and interventions; review adherence and comfort issues 4. Consider Patient Preferences 5. Identify relevant evidence for important outcomes 9. Decide and communicate about decision(s) Implementation/withholding Continuation/discontinuation 10. Reassess at regular intervals Benefits Feasibility Adherence Alignment with preferences 10

Murray Mills is an 87 Year-Old Male Accompanied by son and daughter 11

Patient s Primary Concerns and Objectives Fatigued Taking too many pills Children concerned about safety Children concerned about the ability to stay at home alone Finances are an issue GROUP DISCUSSION 12

Complete Review of Care Plan Probable Alzheimer Congestive heart failure Osteoarthritis Osteoporosis Insomnia Diabetes mellitus, type 2 Benign Prostatic Hyperplasia Review of Medical Data MMSE 23/30 (25/30 6 months prior) BP & HR 110/70, 54 seated; 100/60, 56 standing Hemoglobin A1c 6.8% (7% 3 months prior) LDL cholesterol 70 (3 months ago) BUN/Cr 40/1.7 Echocardiogram EF 30% (1 year ago) Current Medical Interventions 13

GROUP DISCUSSION Adherence/Comfort Forgets evening meds due to fatigue Doesn t check sugars due to discomfort of finger sticks 14

GROUP DISCUSSION Patient Preferences Stay alive Optimize quality of life Reduce out-of-pocket expenses Remain at home despite 3 years of diagnosed Alzheimer 15

GROUP DISCUSSION Evidence for Important Outcomes Donepezil re: maintaining function and/or delaying institutionalization Mixed results and modest effects Many studies do not examine these outcomes Memantine no benefit in mild Alzheimer Benefit from bisphosphonates may persist 5 years after cessation, if taken for at least 5 years Tight glycemic control may cause more harm Liberalize A1c goal 16

GROUP DISCUSSION Prognosis Murray s life expectancy 87 year-old male median = 3.2-4.7 years With Alzheimer median = 2.7-3.3 years Ongoing cognitive decline likely Progressive decline in IADLs 17

GROUP DISCUSSION Medication Interactions Fatigue: Bradycardia Metoprolol Donepezil Hypoglycemia Statin Poor sleep Zolpidem Insomnia Donepezil nightmares Zolpidem may not last entire night 18

Medication Interactions CHF?metformin Alzheimer zolpidem Osteoporosis zolpidem CRI alendronate Hyperlipidemia statin GROUP DISCUSSION 19

Balance of Benefits and Harms Re-evaluate therapies for: Diabetes Insomnia Dyslipidemia CHF Cognitive decline Osteoporosis GROUP DISCUSSION 20

Decide and Communicate GROUP DISCUSSION 21

Reassess at Regular Intervals Benefits Feasibility Adherence Alignment with goals/preferences CONCLUSION Do any of you have cases that you would like to be presented? 22

Edward Perrin, MD Scott Bolhack, MD Sandra Brownstein, PharmD Paige Hector, LMSW Guiding Principles: The Care Of Older Adults With Multimorbidity Fall Symposium Arizona Geriatrics Society November 8, 2013 23